A new target for aspirin

Edward A. O'Neill ()
Additional contact information
Edward A. O'Neill: Merck Research Laboratories

Nature, 1998, vol. 396, issue 6706, 15-17

Abstract: Whereas low doses of aspirin relieve most minor aches and pains, high doses are used to treat chronic inflammatory diseases such as rheumatoid arthritis. Is there any physiological basis for the different effects at high doses? According to a new study there is. High doses of aspirin inhibit IKB kinase-b(IKK-b), and these results may help us to separate the therapeutic benefits of high-dose aspirin from its toxic side effects.

Date: 1998
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/23810 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:396:y:1998:i:6706:d:10.1038_23810

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/23810

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().